Learn About Transthyretin Amyloid Cardiomyopathy
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Trustees Of Columbia University In The City Of New York
Mathew Maurer is an Advanced Heart Failure and Transplant Cardiologist and a Cardiologist in New York, New York. Dr. Maurer is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. His top areas of expertise are Cardiac Amyloidosis, Primary Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Heart Transplant, and Transcatheter Aortic Valve Replacement (TAVR).
Cleveland Clinic Main Campus
Mazen Hanna is a Cardiologist in Cleveland, Ohio. Dr. Hanna has been practicing medicine for over 33 years and is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. His top areas of expertise are Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Primary Amyloidosis, Heart Transplant, and Tenotomy.
Pablo Pavia-Garcia practices in Majadahonda, Spain. Mr. Pavia-Garcia is rated as an Elite expert by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. His top areas of expertise are Transthyretin Amyloid Cardiomyopathy, Cardiomyopathy, Transthyretin Amyloidosis, Heart Transplant, and Pacemaker Implantation.
Summary: Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid ...
Summary: The objective of this study is to determine the association of clinically prescribed, on-label, TTR stabilizing therapy (e.g. tafamidis or acoramidis) with levels of circulating transthyretin amyloid aggregates (TAAs, a surrogate for amyloid disease activity) measured serially over time in patients with transthyretin cardiac amyloidosis (ATTR-CA). To accomplish this objective, the hypothesis that ...